

Mr. GORDON. In the Keen study, in the placebo group 30 percent were over 70 years old, and in the tolbutamide group there was 18 percent who were over 70.

According to the Biometric Society report, the difference is statistically significant at the 5-percent level. Do you know the comparable difference in the UGDP? It was much smaller, was it not?

Dr. MEIER. Yes, the UGDP was conducted with very careful randomization, as described in our report. The Keen study used a much more informal kind of allocation scheme, and indeed, in respect to age, the Keen study had a much wider discrepancy between the groups than did the UGDP.

Mr. GORDON. So the baseline characteristics were more similar in the UGDP than they were in the Keen study.

Dr. MEIER. Yes.

Mr. GORDON. I just wanted to clear that up.

The CHAIRMAN. Is there any other observation any of you gentlemen have on any aspect of this?

Well, the committee wants to thank you very much for taking the time to come here and present the results of your study for the record of this committee. We appreciate it very much. Thank you.

If you have anything supplementary that occurs to you that you think will be useful for the record, the record will be opened for another 2 weeks and you may submit it for printing in the record.

Our next witnesses will be Dr. Robert Bradley, chairman of the Committee on the Care of the Diabetic, Joslin Clinic, Boston, Mass., and Mr. Neil Chayet, counsel.

The committee appreciates you gentlemen taking the time to appear before the committee. You may present your statement however you desire. It will be printed in full in the record.¹

**STATEMENT OF NEIL L. CHAYET, COUNSEL, ACCOMPANIED BY
ROBERT F. BRADLEY, M.D., CHAIRMAN, COMMITTEE FOR THE
CARE OF THE DIABETIC, JOSLIN CLINIC, BOSTON, MASS.**

Mr. CHAYET. Thank you very much, Senator.

My name is Neil L. Chayet. I am a member of the law firm of Chayet & Sonnenreich, and I appear as counsel for the Committee on the Care of the Diabetic.

The CHAIRMAN. Counsel for whom?

Mr. CHAYET. The Committee on the Care of the Diabetic.

The CHAIRMAN. Are you also counsel for the Medical Tribune?

Mr. CHAYET. I would be glad, Senator, to submit it, a list of all my clients, if you care to subpoena it. I still believe, however, in the concept of attorney-client privilege and the confidentiality of that relationship, which I know does not mean that much around here anymore, but I still value it very highly.

If you care to subpoena a list of my clients, I would be glad to provide it. We have many clients and represent many groups, individuals, publications, and others.

The CHAIRMAN. You are the first witness we have had who is embarrassed about whom he represented.

¹ See prepared statement, page 13620.